Kidney disease drug study: how does cenerimod behave?
NCT ID NCT05004311
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at how the drug cenerimod is processed in people with severe kidney impairment compared to healthy people. A total of 16 participants took a single 0.5 mg dose of cenerimod. Researchers measured drug levels in the blood and checked safety markers like heart rhythm and blood pressure. The goal was to understand if kidney problems change how the drug works, which could guide future dosing recommendations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cenerimod
What this could lead to
If successful, this study could help doctors understand how to dose cenerimod safely in patients with severe kidney disease.
What could go wrong
This is a very early, small study (16 people) focused on drug levels, not on treating any disease. Results may not apply to broader populations or predict long-term safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BlueClinical Phase 1 Hospital de Prelado
Porto, 4250-449, Portugal